Exclusive: A first-time CEO launches startup to bring AI into the lab

Michelle Lee's startup Medra raises $11M to build AI-powered lab robots, attracting Genentech and others as customers. The Stanford PhD aims to automate 70% of lab instruments with flexible robotic sy...

endpoints.news

AI Day 2025

Biopharma’s relationship with AI is reaching a tipping point. While Big Pharma doubles down on AI to streamline development, a wave of startups is betting the tech can overhaul R&D from the ground up....

events.endpoints.news

In first-of-its-kind setup, Lilly offers startups free access to its AI models in exchange for data

Eli Lilly is offering an unusual deal to any biotech: contribute some data, and in exchange, get access to many of Lilly's own AI models. The initiative, called TuneLab, debuted ...

endpoints.news

Exclusive: Neuro startup Leal raises $30M Series A for schizophrenia and ALS trials

Leal Therapeutics raises Series A funding led by SV Health Investors for neurology drugs LTX-001 and LTX-002. CEO Asa Abeliovich plans clinical trials through 2026.

endpoints.news

Exclusive: OpenAI, Retro Bio detail lab results with AI protein model, plan use in drug program

OpenAI and Retro Biosciences report AI-made proteins showed 50x better cell reprogramming using modified Yamanaka factors, with potential therapeutic applications

endpoints.news

Exclusive: Formation licenses first drug since $372M raise, eyes more deals in 2025

Formation Bio licenses first-in-class anti-CD226 antibody from IMIDomics for IBD treatment, marking first drug acquisition since $372M Series D raise in 2023.

endpoints.news

Revolution and Iambic to combine data and AI models in R&D deal for cancer drugs

Revolution Medicines has become one of the industry's most valuable pre-commercial companies thanks to its pipeline of clinical-stage cancer drugs. CEO Mark Goldsmith is pressing ahead on ...

endpoints.news

Biopharma's 20 highest-paid CEOs of 2024 with $20M+ paydays

Biopharma CEO median pay hit $4.73M in 2024, up 40%. 20 CEOs made over $20M, including Pfizer's Bourla, Vertex's Kewalramani, Amgen's Bradway & Royalty Pharma's Legorreta.

endpoints.news

KalVista CEO says FDA review proceeded normally, was unaware of Makary's rejection ask

The company felt 'fairly blindsided' upon reading the report that FDA Commissioner Marty Makary had briefly yet unsuccessfully tried to intervene in the review of its newly-approved HAE drug.

endpoints.news

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

FDA approves KalVista Pharmaceuticals' sebetralstat for hereditary angioedema after controversy involving FDA Commissioner Makary's attempted intervention in review process

endpoints.news

China’s rise splits US biotech investors: Cash in, or counter?

US investors debate response to China's rise in drug development, with some seeing a national security threat while others embrace collaboration. FDA and policymakers consider reforms to maintain comp...

endpoints.news

FDA head Makary’s short-lived CRL ask on KalVista’s drug raises more concerns of political intervention

FDA Commissioner Marty Makary’s unsuccessful attempt to intervene in an ongoing drug review, as described by multiple agency sources, raises further concerns about the regulator under its new leadersh...

endpoints.news

Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say

FDA Commissioner Marty Makary reportedly attempted to reject KalVista Pharmaceuticals' drug application, sources said. An HHS spokesperson calls the claim 'totally false.'

endpoints.news

Basecamp pitches a fix for AI bio's 'data wall'

Basecamp Research's global expeditions built BaseData, containing 9.8B protein sequences - 10x larger than public datasets - to advance AI biology models with Nvidia

endpoints.news

Exclusive: Rebooting dead human brains, a biotech startup seeks to reinvent early drug testing work

Startup Bexorg, led by Zvonimir Vrselja, keeps human brains alive to test drugs. Their BrainEx system sustains brain cells for 24 hours to improve drug development and reduce animal testing.

endpoints.news

Recursion to lay off 20% of staff, a month after slashing its pipeline

The Salt Lake City-based biotech disclosed the job cuts in an SEC filing on Tuesday morning. More than 150 employees are likely being let go.

endpoints.news

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

MIT scientists unveil Boltz-2, a new AI model predicting drug binding affinities. Led by Gabriele Corso, Saro Passaro & Jeremy Wohlwend, it outperforms previous AI methods in drug discovery.

endpoints.news

Exclusive: Tech VC Amplify raises $200M for first biotech fund, hires Elliot Hershberg as new partner

The biotech fund — officially called Amplify Bio Fund I — plans to make about 20 investments exclusively in pre-seed, seed and Series A rounds.

endpoints.news

Q&A: Sandoz CEO Richard Saynor on generic GLP-1s, Trump's industry impact, and Mark Cuban's company

Richard Saynor discusses his 35-year career in generics, Sandoz's 80% stock rise since the Novartis spinoff, and views on drug pricing and FDA changes.

endpoints.news

Exclusive: Toronto biotech ProteinQure nears the clinic with peptide platform as it raises $11M Series A

ProteinQure raises $11M Series A led by Heron Rock to advance PQ203, a peptide-drug conjugate for triple-negative breast cancer, into clinical trials by Q3, pivoting from quantum to AI.

endpts.com

Post-Hoc: AI bio needs to heed the overhyped history of CRISPR

Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, responding to DeepMind CEO's disease cure claims.

endpts.com

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Biotech companies face financial strain from expensive long-term leases signed during pandemic boom, with Ginkgo Bioworks, Prime Medicine & others struggling with high lease obligations amid market do...

endpts.com

Exclusive: Datavant to acquire real-world data specialist Aetion, doubling life sciences team

Datavant acquires Aetion in health data merger. Deal doubles life sciences team to 400. CEO Kyle Armbrester says company has $1B+ revenue. Terms undisclosed. More M&A expected.

endpts.com

Recursion cuts nearly half of its pipeline, including its most advanced program

Recursion has cut five drug programs as CEO Chris Gibson focuses on 'winners' in its pipeline.

endpts.com

Iambic debuts next version of AI model Enchant, driving new way for drug R&D

Iambic Therapeutics enhances AI model Enchant v2 with 10x more training data, improving drug property predictions.

endpts.com

Exclusive: Ex-Calico scientist launches Stately Bio with new way to study cells

Stately Bio has raised a $12 million seed round led by AIX Ventures to advance machine learning techniques that recognize signals from simple images of living cells.

endpts.com

The Endpoints Slack interview: Arc Institute's Patrick Hsu on investing, AI and new ways of research

An interview with Patrick Hsu, 31, Harvard PhD grad and CRISPR pioneer, who co-founded Arc Institute and helped develop Evo 2, a biology-focused AI model.

endpts.com

How pharma is reacting to ‘Liberation Day’: Join us tomorrow for Post-Hoc Live!

Live stream podcast tomorrow at 12pm ET with Drew Armstrong, Max Bayer & Anna Brown discussing pharma industry's response to Trump administration tariffs, including lobbying & manufacturing changes.

endpts.com

Exclusive: Can AI replace animal testing? A new biotech launches to find out

Brandon White launches Axiom, a biotech using AI to predict drug toxicity, with $15M seed funding. Former Uber employee aims to replace animal testing with simulation models.

endpts.com

New fund will pressure flailing biotechs, as investor frustration boils over

Nicholas Johnston launches Alis Biosciences, targeting struggling biotechs with $30B in trapped capital and aiming to return cash to shareholders.

endpts.com